BRPI0620566B8 - composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip - Google Patents
composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vipInfo
- Publication number
- BRPI0620566B8 BRPI0620566B8 BRPI0620566A BRPI0620566A BRPI0620566B8 BR PI0620566 B8 BRPI0620566 B8 BR PI0620566B8 BR PI0620566 A BRPI0620566 A BR PI0620566A BR PI0620566 A BRPI0620566 A BR PI0620566A BR PI0620566 B8 BRPI0620566 B8 BR PI0620566B8
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- vip
- prophylactic
- therapeutic treatment
- hypertension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2005906947 | 2005-12-09 | ||
AU2005906947A AU2005906947A0 (en) | 2005-12-09 | VIP fragments and methods of use | |
PCT/AU2006/001869 WO2007065226A1 (fr) | 2005-12-09 | 2006-12-08 | Fragments de vip et méthodes d'utilisation |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0620566A2 BRPI0620566A2 (pt) | 2011-11-16 |
BRPI0620566B1 BRPI0620566B1 (pt) | 2018-07-24 |
BRPI0620566B8 true BRPI0620566B8 (pt) | 2021-05-25 |
Family
ID=38122420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0620566A BRPI0620566B8 (pt) | 2005-12-09 | 2006-12-08 | composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip |
Country Status (20)
Country | Link |
---|---|
US (4) | US8470778B2 (fr) |
EP (2) | EP1976548B1 (fr) |
JP (3) | JP5449778B2 (fr) |
KR (2) | KR101404561B1 (fr) |
CN (2) | CN101325964B (fr) |
AR (2) | AR058308A1 (fr) |
AU (1) | AU2006322656B2 (fr) |
BR (1) | BRPI0620566B8 (fr) |
CA (2) | CA2952475C (fr) |
DK (2) | DK2783697T3 (fr) |
ES (2) | ES2621864T3 (fr) |
HK (1) | HK1122746A1 (fr) |
IL (3) | IL192046A (fr) |
NZ (4) | NZ569401A (fr) |
PL (1) | PL1976548T3 (fr) |
PT (1) | PT1976548E (fr) |
RU (1) | RU2466738C2 (fr) |
TW (1) | TWI402273B (fr) |
WO (1) | WO2007065226A1 (fr) |
ZA (1) | ZA200805837B (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ552130A (en) * | 2004-06-11 | 2009-10-30 | Vectus Biosystems Ltd | Compositions and methods for the treatment of cardiovascular disease |
KR20080082597A (ko) * | 2005-07-28 | 2008-09-11 | 글로벌 리서치 테크놀로지스, 엘엘씨 | 공기로부터 이산화탄소의 제거 |
BRPI0620566B8 (pt) | 2005-12-09 | 2021-05-25 | Vectus Biosystems Ltd | composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip |
US8841255B2 (en) * | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US8334257B2 (en) | 2005-12-20 | 2012-12-18 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
EP3412300A1 (fr) | 2008-06-27 | 2018-12-12 | Duke University | Agents thérapeutiques comprenant des peptides de type élastine |
ES2603963T3 (es) * | 2008-10-17 | 2017-03-02 | Vectus Biosystems Limited | Composiciones y métodos para el tratamiento de trastornos renales |
CN101434649B (zh) * | 2008-12-12 | 2012-04-25 | 余榕捷 | 一种环七肽及其制备方法和应用 |
MY180681A (en) * | 2009-04-02 | 2020-12-06 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of aortic fibrosis |
BR112012003327A2 (pt) * | 2009-08-14 | 2017-06-06 | Phasebio Pharmaceuticals Inc | peptídeos intestinais vasoativos modificados |
ES2669190T3 (es) | 2011-06-06 | 2018-05-24 | Phasebio Pharmaceuticals, Inc. | Uso de péptidos intestinales vasoactivos modificados en el tratamiento de la hipertensión |
UA118111C2 (uk) * | 2013-09-17 | 2018-11-26 | Вектус Байосистемз Лімітед | Сполука та композиція для лікування гіпертензії та/або фіброзу |
US9375638B2 (en) * | 2014-01-02 | 2016-06-28 | Lloyd A. Weaver | Game console switch box |
AU2015255752B2 (en) | 2014-05-08 | 2020-07-23 | Immunoforge Co., Ltd. | Methods and compositions for treating Cystic Fibrosis |
US10688156B2 (en) | 2015-02-09 | 2020-06-23 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3862927A (en) * | 1973-02-26 | 1975-01-28 | Sami I Said | Process for preparation of vasoactive intestinal peptide |
US4016258A (en) * | 1975-08-05 | 1977-04-05 | Said Sami I | Vasoactive intestinal peptide from fowl |
US4237046A (en) * | 1979-04-27 | 1980-12-02 | Miklos Bodanszky | Polypeptides and methods of preparation |
GB8427651D0 (en) * | 1984-11-01 | 1984-12-05 | Beecham Group Plc | Compounds |
NZ221440A (en) * | 1986-08-20 | 1991-11-26 | Genetic Systems Corp | Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections |
US5972883A (en) * | 1993-03-16 | 1999-10-26 | Yeda Research And Development Co. Ltd. | Method for the treatment of neurodegenerative diseases by administering VIP, an analogue, fragment or a conjugate thereof |
US5808037A (en) * | 1995-09-15 | 1998-09-15 | Ramareddy Venkata Guntaka | Oligomers which inhibit expression of collagen genes |
US20020115609A1 (en) * | 1997-07-14 | 2002-08-22 | Hayat Onyuksel | Materials and methods for making improved micelle compositions |
US5892162A (en) * | 1997-11-18 | 1999-04-06 | Southwest Research Institute | Apparatus and method for inspection of pipes and tubes using guided wave probe |
AU780261B2 (en) * | 1999-10-29 | 2005-03-10 | Nitromed, Inc. | Methods of treating vascular diseases characterized by nitric oxide insufficiency |
DE60142351D1 (de) * | 2000-10-20 | 2010-07-22 | Amylin Pharmaceuticals Inc | Behandlung von hypoaktivem myokard und diabetischer herzmyopathie mit einem glp-1 peptid |
AU2002220720B2 (en) * | 2000-11-28 | 2006-09-14 | Mondobiotech Ag | Compounds with the biological activity of vasoactive intestinal peptide for the treatment of pulmonary and arteriolar hypertension |
US6911430B2 (en) * | 2003-10-01 | 2005-06-28 | Vipogen, Llc | Compositions and methods for treating ileus |
WO2005113593A1 (fr) * | 2004-05-21 | 2005-12-01 | Eli Lilly And Company | Agonistes peptidiques selectifs du recepteur vpac2 |
JP2008500401A (ja) * | 2004-05-21 | 2008-01-10 | アキュ−ブレイク テクノロジーズ インコーポレーテッド | 複数のセグメントを含む、刻み目のある医薬錠剤 |
NZ552130A (en) * | 2004-06-11 | 2009-10-30 | Vectus Biosystems Ltd | Compositions and methods for the treatment of cardiovascular disease |
BRPI0620566B8 (pt) | 2005-12-09 | 2021-05-25 | Vectus Biosystems Ltd | composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip |
WO2008073146A2 (fr) * | 2006-07-06 | 2008-06-19 | University Of Wyoming | Procédé et appareil pour induire le clivage par pyrolyse dans des peptides et des protéines |
ES2603963T3 (es) * | 2008-10-17 | 2017-03-02 | Vectus Biosystems Limited | Composiciones y métodos para el tratamiento de trastornos renales |
MY180681A (en) * | 2009-04-02 | 2020-12-06 | Vectus Biosystems Pty Ltd | Compositions and methods for treatment of aortic fibrosis |
-
2006
- 2006-12-08 BR BRPI0620566A patent/BRPI0620566B8/pt active IP Right Grant
- 2006-12-08 WO PCT/AU2006/001869 patent/WO2007065226A1/fr active Application Filing
- 2006-12-08 TW TW095145955A patent/TWI402273B/zh active
- 2006-12-08 RU RU2008127877/15A patent/RU2466738C2/ru active
- 2006-12-08 ES ES14170486.6T patent/ES2621864T3/es active Active
- 2006-12-08 EP EP06817603.1A patent/EP1976548B1/fr active Active
- 2006-12-08 CN CN2006800463844A patent/CN101325964B/zh active Active
- 2006-12-08 CN CN201310356642.0A patent/CN103450345B/zh active Active
- 2006-12-08 ES ES06817603.1T patent/ES2523858T3/es active Active
- 2006-12-08 NZ NZ569401A patent/NZ569401A/en unknown
- 2006-12-08 CA CA2952475A patent/CA2952475C/fr active Active
- 2006-12-08 NZ NZ597677A patent/NZ597677A/xx unknown
- 2006-12-08 PL PL06817603T patent/PL1976548T3/pl unknown
- 2006-12-08 EP EP14170486.6A patent/EP2783697B1/fr active Active
- 2006-12-08 AU AU2006322656A patent/AU2006322656B2/en active Active
- 2006-12-08 DK DK14170486.6T patent/DK2783697T3/en active
- 2006-12-08 KR KR1020087016565A patent/KR101404561B1/ko active IP Right Grant
- 2006-12-08 CA CA2632581A patent/CA2632581C/fr active Active
- 2006-12-08 JP JP2008543613A patent/JP5449778B2/ja active Active
- 2006-12-08 NZ NZ604248A patent/NZ604248A/en unknown
- 2006-12-08 US US12/096,768 patent/US8470778B2/en active Active
- 2006-12-08 KR KR1020147006727A patent/KR20140041943A/ko active Search and Examination
- 2006-12-08 NZ NZ623674A patent/NZ623674A/en unknown
- 2006-12-08 PT PT68176031T patent/PT1976548E/pt unknown
- 2006-12-08 DK DK06817603.1T patent/DK1976548T3/da active
- 2006-12-11 AR ARP060105452A patent/AR058308A1/es not_active Application Discontinuation
-
2008
- 2008-06-10 IL IL192046A patent/IL192046A/en active IP Right Grant
- 2008-07-03 ZA ZA2008/05837A patent/ZA200805837B/en unknown
-
2009
- 2009-03-26 HK HK09102915.9A patent/HK1122746A1/xx unknown
-
2012
- 2012-06-13 JP JP2012133977A patent/JP5730820B2/ja active Active
-
2013
- 2013-02-07 IL IL224609A patent/IL224609A/en active IP Right Grant
- 2013-05-28 US US13/903,227 patent/US8916523B2/en active Active
- 2013-12-26 JP JP2013269991A patent/JP5847793B2/ja active Active
-
2014
- 2014-01-19 IL IL230534A patent/IL230534A/en active IP Right Grant
- 2014-11-17 US US14/542,929 patent/US9340583B2/en active Active
-
2016
- 2016-04-19 US US15/132,475 patent/US9732136B2/en active Active
-
2017
- 2017-07-28 AR ARP170102152A patent/AR109274A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0620566B8 (pt) | composição, composição para o tratamento profilático ou terapêutico de fibrose miocardial ou uma condição associada, composição para o tratamento profilático ou terapêutico de hipertensão, uso de uma composição, uso de vip ou de um fragmento do mesmo e uso de um vip | |
BRPI0511367A (pt) | uso de uma composição,composição, uso de vip e/ou de um fragmento ativo do mesmo | |
MY160560A (en) | Compositions and methods for treatment of kidney disorders | |
MXPA06008495A (es) | Factor proliferativo gastrointestinal y usos del mismo. | |
WO2005120557A3 (fr) | Inhibition du recepteur proteique stimulant les macrophages (ron) | |
NO20060328L (no) | Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser | |
IL232501A (en) | Peptide or polypeptide-resistant protein analogs and their uses | |
DK1377280T3 (da) | Fyldmidler som mæthedsfornemmelsesgivende midler | |
WO2006023844A3 (fr) | Compositions et procedes comportant des antagonistes de recepteur active par la proteinase | |
WO2007076055A3 (fr) | Compositions et methodes comprenant l'utilisation d'antagonistes du recepteur active par des proteases | |
WO2007035716A3 (fr) | Compositions de proteines rap specifiques des proteines contenant du cr, et leurs utilisations | |
WO2007075439A3 (fr) | Compositions et methodes pour traiter l'obesite et des troubles metaboliques associes | |
TW200716172A (en) | Pharmaceutical compositions for treating lower motor neuron diseases | |
MY142044A (en) | Endoparasiticidal compositions for topical application | |
UA87841C2 (ru) | Композиция, которая содержит амброксол, для местного применения | |
CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
WO2008079270A3 (fr) | Coadministration d'alpha-foetoprotéine et d'un agent immunomodulateur pour traiter la sclérose en plaques | |
EP2510941A3 (fr) | Procédés de traitement de la sclérose en plaques par administration d'une alpha-foetoprotéine combinée à un antagoniste de l'intégrine | |
EA200800181A1 (ru) | Фармацевтическая композиция glp-1 | |
SI1622939T1 (sl) | Akrivne variante il-18 vezavnega proteina in medicinske uporabe le-tega | |
EA200600404A1 (ru) | Пероральные препаративные формы кладрибина | |
UA107177C2 (uk) | Імуногенна композиція цвс2 та спосіб приготування такої композиції | |
WO2003093419A3 (fr) | Prevention de lymphoedeme secondaire avec un adn de vegf-d | |
GB0616061D0 (en) | Peptides and uses thereof | |
TW200602055A (en) | Spray dried pharmaceutical compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/07/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |